5 Matching Annotations
  1. Last 7 days
  2. pmc.ncbi.nlm.nih.gov pmc.ncbi.nlm.nih.gov
    CRISPR-Drug Combinatorial Screening Identifies Effective Combination Treatments for MTAP-deleted cancer
    1
    Visit annotations in context

    Tags

    Annotators

    URL

    pmc.ncbi.nlm.nih.gov/articles/PMC13014710/
  3. Mar 2025
  4. pmc.ncbi.nlm.nih.gov pmc.ncbi.nlm.nih.gov
    Impact of Co-mutations and Transcriptional Signatures in Non–Small Cell Lung Cancer Patients Treated with Adagrasib in the KRYSTAL-1 Trial
    1
    Visit annotations in context

    Tags

    Annotators

    URL

    pmc.ncbi.nlm.nih.gov/articles/PMC11911804/
  5. Nov 2023
  6. aacrjournals.org aacrjournals.org
    MRTX1719 Is an MTA-Cooperative PRMT5 Inhibitor That Exhibits Synthetic Lethality in Preclinical Models and Patients with MTAP-Deleted Cancer
    1
    Visit annotations in context

    Tags

    Annotators

    URL

    aacrjournals.org/cancerdiscovery/article/13/11/2412/729848/MRTX1719-Is-an-MTA-Cooperative-PRMT5-Inhibitor
  7. Oct 2022
  8. www.nature.com www.nature.com
    A selective and orally bioavailable VHL-recruiting PROTAC achieves SMARCA2 degradation in vivo
    1
    Visit annotations in context

    Tags

    Annotators

    URL

    nature.com/articles/s41467-022-33430-6
  9. Jul 2021
  10. onlinelibrary.wiley.com onlinelibrary.wiley.com
    Radioresistance of KRAS/TP53‐Mutated Lung Cancer can be overcome by Radiation Dose Escalation or EGFR Tyrosine Kinase Inhibition In Vivo
    1
    Visit annotations in context

    Tags

    Annotators

    URL

    onlinelibrary.wiley.com/doi/full/10.1002/ijc.32598